The medical journal Annals of Pharmacotherapy has published an article, “Dipeptidyl Peptidase-4 Inhibitors and Inflammatory Bowel Disease Risk: A Meta-analysis”, which concludes that dipeptidyl peptidase-4 (DPP-4) inhibitors increase the risk of Crohn’s disease (CD). It goes on to point out that these DPP-4 inhibitor diabetes drugs, such as … [Read more...]